Mostrando las entradas con la etiqueta hormonas. Mostrar todas las entradas
Mostrando las entradas con la etiqueta hormonas. Mostrar todas las entradas

jueves, 27 de agosto de 2009

La terapia hormonal,puede aumentar el riego de morir en los hombres con Cáncer de prostata y Enfermedad cardiaca

From Medscape Medical News

Hormone Therapy May Increase Risk for Death in Men With Prostate Cancer and Heart Disease

Nick Mulcahy

Physician Rating: 3 stars ( 3 Votes )
Rate This Article:

August 26, 2009 – In localized or locally advanced prostate cancer, the use of neoadjuvant hormone therapy was associated with a nearly 2-fold risk for death in men who also had a history of coronary artery disease.

This finding comes from a retrospective study of 5077 men who were treated with brachytherapy for their cancer, 30% of whom received neoadjuvant hormone therapy for a median treatment duration of 4 months.

The hormone therapy consisted of both a luteinizing hormone-releasing hormone agonist (leuprolide or goserelin) and a nonsteroidal antiandrogen (bicalutamide or flutamide).

On the bright side of the data, there was no increase in all-cause mortality among men treated with hormone therapy who had either no cardiovascular comorbidity or a single coronary artery disease risk factor, such as diabetes mellitus, hypercholesteremia, or hypertension. Smoking and a family history of heart disease were not evaluated as risk factors.

The study was published in the August 26 issue of the Journal of the American Medical Association.

In an interview with Medscape Oncology, the study's lead author stressed that only 5% of the men in the study — a "small subgroup" — had coronary artery disease (congestive heart failure or past heart attack).

"Our results suggest that for these men, either hormonal therapy not be used in the treatment of their prostate cancer or their underlying heart disease be addressed by a primary-care physician and/or a cardiologist before they are considered for hormonal therapy," said Akash Nanda, MD, PhD, from Brigham and Women's Hospital and the Dana-Farber Cancer Institute in Boston, Massachusetts.

This study should heighten awareness about the potential for harm with neoadjuvant hormone therapy in select men.

Dr. Nanda acknowledged that it is not known if treatment for heart disease would improve outcome. "The study does not address whether or not treatment for coronary artery disease potentially changes the risk for these patients," he said.

Dr. Nanda and his coauthors concluded that "this study should heighten awareness about the potential for harm with neoadjuvant hormone therapy in select men."

Study Details

Several clinical trials have shown that adding hormonal therapy to radiation therapy in the treatment of aggressive prostate cancer leads to an increase in survival, observed Dr. Nanda. However, a recent analysis (JAMA. 2008:299:289-295) indicated that "this may not be the case for men with coexisting illnesses," according to Dr. Nanda. The purpose of the new study was to identify comorbidities that might affect survival.

To that end, the investigators looked at 5077 men with clinical stage T1 to T3 N0 M0 prostate cancer treated between 1997 and 2006 at the Chicago Prostate Cancer Center, a community practice in Westmont, Illinois. Men were referred to this center on the basis of their interest in or candidacy for brachytherapy.

Among the men, 2653 (52.3%) had no history of a cardiovascular comorbidity, 2168 (42.7%) had a coronary artery disease risk factor, and 256 (5%) had coronary artery disease. The median age of the men was 69.5 years, and 557 (10.9%) had received supplemental external-beam radiation.

Most of the men in the study (70%) did not receive neoadjuvant hormone therapy and served as comparators for the men who did.

Neoadjuvant hormone therapy use was not significantly associated with an increased risk for all-cause mortality in men with no comorbidity (9.6% vs 6.7%; adjusted hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.72 - 1.32; P = .86) or a single coronary artery disease risk factor (10.7% vs 7.0%; adjusted HR, 1.04; 95% CI, 0.75 - 1.43; P = .82) after median follow-ups of 5.0 and 4.4 years, respectively.

However, for men with coronary artery disease, the therapy was significantly associated with an increased risk for all-cause mortality (26.3% vs 11.2%; adjusted HR, 1.96; 95% CI, 1.04 - 3.71; P = .04). These men had a median follow-up of 5.1 years.

In arriving at these findings, the investigators adjusted for age, treatment year, supplemental external-beam radiation therapy, treatment propensity score, and known prostate cancer prognostic factors (such as Gleason score).

The authors also noted that, in other research in different settings, hormone therapy has been associated with a variety of adverse effects, including increased risk for cardiovascular death.

More on Clinical Significance

Dr. Nanda and his colleagues recommend that, in men with favorable-risk prostate cancer and a history of coronary artery disease, alternative strategies to brachytherapy and hormone therapy be considered. These include active surveillance, treatment with external-beam radiation alone, and prostatectomy. In such men, hormone therapy is not really needed to "maximize outcome" anyway, explained Dr. Nanda. Instead, hormone therapy is used to reduce the size of the gland, ensuring that brachytherapy is not obstructed by the arch of the pubic bone.

Hormone therapy is needed to maximize outcome.

However, in men with unfavorable-risk prostate cancer, hormone therapy offers a survival benefit. "This is a tougher decision because hormone therapy is needed to maximize outcome," said Dr. Nanda. The risks and benefits of hormone therapy must be balanced; as noted above, appropriate medical evaluation or treatment is needed before hormone therapy is used in this setting, Dr. Nanda said.

Dr. Nanda also pointed out that the findings were limited to brachytherapy and, as a result, not necessarily generalizable to men with prostate cancer who are treated with external-beam radiation. "Other investigators will want to validate these findings in other settings," he said.

The authors also note that the duration and extent of hormone therapy are variables in need of study. "Men with locally advanced prostate cancer are frequently treated with 2 to 3 years of hormone therapy in combination with external-beam radiation therapy," they write.

The researchers have disclosed no relevant financial relationships.

JAMA. 2009;302:866-873.

martes, 25 de agosto de 2009

Evaluacion hormona en el Hombre infertil

1: Gynecol Obstet Fertil. 2008 May;36(5):551-6. Epub 2008 May 6.Click here to read Links

[Hormonal evaluation in infertile men]

[Article in French]

Service d'endocrinologie de la reproduction, EA 1533, faculté Paris-VI, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris (AP-HP), 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.

The purpose of hormonal testing in infertile men is to screen treatable causes of infertility. Recommendations of the American Urological Association and the Society of Reproductive Medicine are to measure serum follicle-stimulating hormone (FSH) and testosterone if there is an abnormally low sperm concentration, impaired sexual function or clinical findings suggestive of endocrinopathy. If testosterone level is low, measurement of total and free or bioavaible testosterone should be performed as well as determination of luteinizing hormone (LH) and prolactin level. This hormonal evaluation can distinguish hypogonadotropic hypogonadism from testicular insufficiency.

PMID: 18462981 [PubMed - indexed for MEDLINE]

relacion entre los niveles sericos de hormonas y la calidad del semen en una clinica de Infertilidad

1: J Androl. 2007 May-Jun;28(3):397-406. Epub 2006 Nov 29.Click here to read Links

Relationships between serum hormone levels and semen quality among men from an infertility clinic.

Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI 48109, and Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, USA. meekerj@umich.edu

Participation rates in epidemiologic studies on semen quality are generally very low, raising concerns as to the potential for selection bias. Since hormones both initiate and maintain spermatogenesis, they may serve as surrogates of semen quality in epidemiologic studies. For this reason, in the present study, we explored the influence and predictive ability of reproductive and thyroid hormones on semen quality among men who were partners in an infertile couple. Between 1999 and 2003, 388 men were recruited from Massachusetts General Hospital Andrology Laboratory for clinical evaluation of fertility status. Fresh semen samples were assessed for quality (concentration, motility and morphology) and the serum levels of hormones, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, sex hormone-binding globulin (SHBG), testosterone, free androgen index, free T4, total T3, and thyroid-stimulating hormone (TSH), were measured. Multiple logistic regression revealed increased odds for below-reference sperm concentration and morphology in men with increased FSH, and decreased odds for below-reference sperm concentration and motility in men with increased inhibin B. When FSH and inhibin B were divided into quintiles, the relationships with sperm concentration showed evidence of a threshold value. However, the ability of specific FSH (10 IU/L) and/or inhibin B (80 pg/mL) cutoff values to predict semen quality was lower than in previous reports. In multiple linear regression analysis, FSH and LH were inversely associated with sperm concentration, motility, and morphology. Inhibin B and free T4 were positively associated with sperm concentration, while there was a suggestive positive association between testosterone and sperm motility. In conclusion, we have found that FSH, LH, inhibin B, testosterone and free T4 levels are associated with human semen parameters. Additional consideration should be given to the utility of serum hormone levels as a surrogate for semen quality in epidemiologic studies in which the collection of semen is difficult due to logistical and/or volunteer rate constraints.

PMID: 17135633 [PubMed - indexed for MEDLINE]

El efecto protector de la Diabetes mellitus,contra el Cáncer de próstata,rol de las Hormonas sexuales.

1: Prostate. 2009 Aug 12. [Epub ahead of print]Click here to read Links

The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones.

Department of Urology, Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

BACKGROUND: Diabetes mellitus (DM) has been associated with decreased risk of prostate cancer (PC) in several reports. Hormonal environment of diabetic patients is believed to be an important contributing factor in this regard. METHODS: Using data from a multi-center case-control study in Iran, base line testosterone, sex hormone binding globulin (SHBG), estradiol, and albumin levels as well as thorough demographic and medical characteristics of 194 newly diagnosed prostate cancer patients were determined. There were 317 ethnicity-matched men with no cancer as controls as well. Data was analyzed for hormones of interest in DM patients regarding their cancer status. RESULTS: Of 511 enrolled patients, twenty-one cases and 63 controls were diagnosed as DM. Patients with DM were significantly less likely to have PC (OR: 0.44, P = 0.003). Time since DM diagnosis was also inversely correlated with the risk of cancer (P trend <>

PMID: 19676082 [PubMed - as supplied by publisher]

clitorisvaginavejigasalud

Bookmark and Share

hormonas yosteoporosis en el hombre

Bookmark and Share